UCHealth Highlands Ranch Hospital

Summary

UCHealth Highlands Ranch Hospital is a medical facility located in Littleton, Colorado. This center is recognized for care of Breast Cancer, Breast cancer, Lung Cancer, Non-Small Cell Lung Cancer, Kidney Cancer and other specialties. UCHealth Highlands Ranch Hospital is involved with conducting 45 clinical trials across 68 conditions. There are 23 research doctors associated with this hospital, such as Bradley R. Corr, Jose M. Pacheco, Anthony D Elias, M.D., and Elizabeth R. Kessler.

Top PIs

Clinical Trials running at UCHealth Highlands Ranch Hospital

Breast Cancer

Prostate Cancer

Bladder Cancer

Ovarian Cancer

Kidney Cancer

Breast cancer

Uterine Cancer

Renal Cell Carcinoma

Small Cell Lung Cancer

Lung Cancer

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Recruiting

2 awards

Phase 3

40 criteria

Radiation and HER2-Targeted Therapy

for Breast Cancer

This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.

Recruiting

2 awards

Phase 3

15 criteria

Low Dose Tamoxifen

for Breast Cancer

This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.

Recruiting

2 awards

Phase 3

8 criteria